DOCSLIB.ORG

Reference Standards

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reference Standards Analytical SERVICES TO HEALTH Reference Standards Reference Standards 2014/04 1 Analytical SERVICES TO HEALTH Reference Standards 2 Analytical SERVICES TO HEALTH Reference Standards Table of Contents Company Profi le page 4 Reference Standards page 6 Why choose Lipomed Reference Standards? page 9 Commitment to Quality page 10 Certifi cate of Analysis page 14 Catalog User Guide page 21 Contact Information page 23 Aqueous Ethanol Standard Solutions page 29 Alphabetical Product List page 31 Alphabetical Index page 189 Catalog Number Index page 197 Substance Class Index page 203 Standard Terms and Conditions of Sale page 207 3 Analytical SERVICES TO HEALTH Reference Standards Company Profi le Lipomed is a private research and development based Health Care Com- pany that serves the worldwide market for Pharmaceuticals and Reference Standards. The headquarters are located in Arlesheim near Basel, Switzerland. Lipomed AG, Switzerland is GMP /GDP and ISO 9001:2008 certifi ed for pro- duction and distribution of Pharmaceuticals and ISO/ IEC 17025:2005 (ACLASS Certifi cate No. AT-1760) accredited for testing of Analytical Refer- ence Standards and ISO Guide 34:2009 (ACLASS Certifi cate No. AR-1761) accredited for Reference Material production. All products distributed by Lipomed Affi liates are manufactured by Lipomed AG and distributed under protocols of Lipomed AG. 4 Analytical SERVICES TO HEALTH Reference Standards Lipomed Inc. in Cambridge, Massachusetts, USA Lipomed Inc. is the sole distributor for the US and Canadian markets for Reference Standards. Lipomed GmbH in Weil am Rhein, Germany Lipomed GmbH serves as a Logistics and Distribution Center for Europe for Reference Standards and Pharmaceuticals. Lipomed GmbH is also the Marketing Authorization Holder for the pharmaceutical products in Europe. It is ISO 9001:2008 certifi ed. Lipomed GmbH in Vienna, Austria The Austrian subsidiary of Lipomed is responsible for the marketing of Lipomed’s products in Austria and Eastern Europe. 5 Analytical SERVICES TO HEALTH Reference Standards Reference Standards Lipomed is a leading producer and supplier of analytical reference materials manufactured according to the highest quality standards currently given to reference materials producer. Indeed, Lipomed holds ISO / IEC 17025:2005 (ACLASS Certifi cate No. AT-1760) and ISO Guide 34:2009 (ACLASS Certifi cate No. AR-1761) accreditations as well as ISO 9001:2008 certifi cation to meet customers’ expectations for quality and reliability, Supplied as native and stable-isotope labeled for mass spectrometry and other analytical techniques, Lipomed reference standards are available as calibrated ready-to-use (RTU) solutions & powders as well as powders in larger pack sizes. This has been done to provide our customers additional fl exibility in choosing the most appropriate form for their needs. Lipomed reference standards currently include the following classes of sub- stances, their deuterated analogues and metabolites such as Glucuronides and Sulfates: • Alcohol & Ethanol Biomarkers • Cannabinoids • Amphetamines & • Cathinones Sympathomimetic amines • Cocaines • Antidepressants • Hallucinogens • Antipsychotics • Opioids • Barbiturates • Other CNS Depressants • Benzodiazepines • Steroids Our range of product offering is continuously expanding in order to assist our customers in providing the highest quality reference materials they need to perform their analysis. If you do not fi nd the product(s) you are looking for please contact us. Lipomed’s reference standards are available worldwide either through Li- pomed offi ces in Europe and in the USA, and through a selected network of appointed distributors for local customer services. Please see page 23 for Lipomed offi ces and page 24 for Lipomed’s appointed distributors. For information about Lipomed’s new Reference Standards, please visit www.lipomed.com. To be updated on the release of new products, please request our newslet- ter by subscribing at: [email protected] All reference standards distributed by Lipomed Inc. and by any other Affi liate or Partner Company under the Lipomed label are manufactured by the ISO certifi ed company Lipomed AG. 6 Analytical SERVICES TO HEALTH Reference Standards Solutions and Powders Available Lipomed’s Reference Standards are available as calibrated ready-to-use (RTU) solutions and as calibrated ready-to-use (RTU) powders fi lled in ampoules or in 20 ml vials respectively. • RTU Solutions • RTU Powders RTU Solutions and RTU Powders are intended for quantitative ready-to-use pur- poses. Accurate weight and / or strength are based on the free drug substance. Lipomed’s Reference Standards are also available as powders in standard pack sizes of 10 mg, 50 mg and 100 mg. Larger quantities might be available upon request. The weight and / or strength are based on the drug substance. RTU Solution Reference Standards Lipomed’s 1mg/ml and 0.1 mg/ml ampoules contain high precision calibrat- ed Reference Standards to an accuracy of 1.000 ± 0.050 mg/ml and 0.100 ± 0.005 mg/ml of free drug substance in sealed amber glass ampoules under argon for added stability. Lipomed’s ampoules are over-fi lled to ensure that the target volume of 1ml can be quantitatively transferred. RTU Powder Reference Standards Lipomed’s 1mg vials contain high precision calibrated freeze-dried Reference Standards to an accuracy of 1.000 ± 0.050 mg of free drug substance in 20ml amber glass septum-capped vials. Instructions for the Safe use of RTU Powder Reference Standards Calibrated standard solutions are prepared in an easy and safe way as follows: 1. Clip off the aluminum center of the cap. 2. Add the solvent of choice through the septum using a gas tight precision syringe. Gently shake and invert the vial several times to ensure complete dissolution of the powder. 3. Withdraw the desired volume of calibrated solution through the septum using a syringe. 7 Analytical SERVICES TO HEALTH Reference Standards Shelf life Stability monitoring is performed on all Reference Standards at appropriate intervals. For most of Lipomed’s Reference Standards, Retest Dates are provided on the Certifi cates of Analysis together with the corresponding batch numbers. Retests are performed by Lipomed prior to the stated retest dates. This allows for a validity extension of the retested batch subject to successful retest, proper storage and unopened ampoules/vials. Updated certifi cates of analysis are available on the website or by e-mail: [email protected] (USA, Canada, Bermuda) and [email protected] (all other countries). Retest and expiry dates should be read as per end of the stated month. Storage Airtight storage at a temperature of 2 – 8 °C in a dark location is recommended, unless otherwise indicated on the label. Use Lipomed's Reference Standards are not qualifi ed for use in controlled GLP and GCP experiments and must not be used in human or animal preclinical or clinical trials. Lipomed reference standards are also not qualifi ed for con- trol of GMP regulated manufacturing. Safety All products mentioned in this catalog have to be considered potentially toxic substances and must be handled by suitably trained staff. 8 Analytical SERVICES TO HEALTH Reference Standards Why choose Lipomed Reference Standards? • Calibrated Reference Standards available in both powder form and as solutions from a single source. • Retest dates instead of expiry dates provided for most of Lipomed Reference Standards’ lot. • Large choice of standard strengths and quantities available: 0.1 mg/ml, 1 mg, 1 mg/ml, 10 mg, 50 mg, 100 mg. • Gram quantities and higher available on request. • Special products available such as alcohol biomarkers, designer drugs, opiates glucuronides, “street heroin”, THCA-A, etc. • Fast delivery from local stocks held in Switzerland, Germany, France and the USA. • High quality Reference Standards supplied with lot-specifi c certifi cates of analysis. • Lot-to-lot consistency regulated by rigorous product specifi cations and quality control SOPs. • Check Lipomed’s quality before ordering: product specifi cations available at www.lipomed.com • Competitive pricing • Lipomed AG is ISO 9001:2008 certifi ed and ISO/IEC 17025:2005 (ACLASS Certifi cate No. AT-1760), ISO Guide 34:2009 (ACLASS Certifi cate No. AR-1761) accredited. 9 Analytical SERVICES TO HEALTH Reference Standards Commitment to Quality Lipomed AG, Switzerland is GMP/GDP and ISO 9001:2008 certifi ed for pro- duction and distribution of Pharmaceuticals and ISO/IEC 17025:2005 (ACLASS Certifi cate No. AT-1760) accredited for testing of Analytical Refer- ence Standards and ISO Guide 34:2009 (ACLASS Certifi cate No. AR-1761) accredited for Reference Material production. All products distributed by Lipomed Affi liates are manufactured by Lipomed AG and distributed under protocols of Lipomed AG. 10 Analytical SERVICES TO HEALTH Reference Standards 11 Analytical SERVICES TO HEALTH Reference Standards CERTIFICATE IQNet and SQS hereby certify that the organisation Lipomed AG 4144 Arlesheim Switzerland Certified area Whole company Field of activity Manufacturing, analysis, packaging and distribution of analytical reference materials and pharmaceuticals has implemented and maintains a Management System which fulfills the requirements of the following standard(s) ISO 9001:2008 Scope No(s): 13 Issued on: 2013-06-16 Validity date: 2016-06-15 Registration Number: CH-37199 Michael Drechsel Roland Glauser President of IQNet CEO SQS IQNet Partners*: AENOR Spain AFNOR Certification France AIB-Vinçotte International Belgium ANCE-SIGE Mexico APCER
Load more

Recommended publications
  • Endogenous Metabolites: JHU NIMH Center Page 1
    S. No. Amino Acids (AA) 24 L-Homocysteic acid 1 Glutaric acid 25 L-Kynurenine 2 Glycine 26 N-Acetyl-Aspartic acid 3 L-arginine 27 N-Acetyl-L-alanine 4 L-Aspartic acid 28 N-Acetyl-L-phenylalanine 5 L-Glutamine 29 N-Acetylneuraminic acid 6 L-Histidine 30 N-Methyl-L-lysine 7 L-Isoleucine 31 N-Methyl-L-proline 8 L-Leucine 32 NN-Dimethyl Arginine 9 L-Lysine 33 Norepinephrine 10 L-Methionine 34 Phenylacetyl-L-glutamine 11 L-Phenylalanine 35 Pyroglutamic acid 12 L-Proline 36 Sarcosine 13 L-Serine 37 Serotonin 14 L-Tryptophan 38 Stachydrine 15 L-Tyrosine 39 Taurine 40 Urea S. No. AA Metabolites and Conjugates 1 1-Methyl-L-histidine S. No. Carnitine conjugates 2 2-Methyl-N-(4-Methylphenyl)alanine 1 Acetyl-L-carnitine 3 3-Methylindole 2 Butyrylcarnitine 4 3-Methyl-L-histidine 3 Decanoyl-L-carnitine 5 4-Aminohippuric acid 4 Isovalerylcarnitine 6 5-Hydroxylysine 5 Lauroyl-L-carnitine 7 5-Hydroxymethyluracil 6 L-Glutarylcarnitine 8 Alpha-Aspartyl-lysine 7 Linoleoylcarnitine 9 Argininosuccinic acid 8 L-Propionylcarnitine 10 Betaine 9 Myristoyl-L-carnitine 11 Betonicine 10 Octanoylcarnitine 12 Carnitine 11 Oleoyl-L-carnitine 13 Creatine 12 Palmitoyl-L-carnitine 14 Creatinine 13 Stearoyl-L-carnitine 15 Dimethylglycine 16 Dopamine S. No. Krebs Cycle 17 Epinephrine 1 Aconitate 18 Hippuric acid 2 Citrate 19 Homo-L-arginine 3 Ketoglutarate 20 Hydroxykynurenine 4 Malate 21 Indolelactic acid 5 Oxalo acetate 22 L-Alloisoleucine 6 Succinate 23 L-Citrulline 24 L-Cysteine-glutathione disulfide Semi-quantitative analysis of endogenous metabolites: JHU NIMH Center Page 1 25 L-Glutathione, reduced Table 1: Semi-quantitative analysis of endogenous molecules and their derivatives by Liquid Chromatography- Mass Spectrometry (LC-TripleTOF “or” LC-QTRAP).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements for the Degree Of
    3-7? CHEMICAL IONIZATION (CI) GC/MS ANALYSIS OF UNDERIVATIZED AMPHETAMINES FOLLOWED BY CHIRAL DERIVATIZATION TO IDENTIFY d AND 1-ISOMERS WITH ION TRAP MASS SPECTROMETRY THESIS Presented to the Graduate Council of the University of North Texas in Partial Fulfillment of the Requirements for the Degree of MASTER OF SCIENCE (Pharmacology) By John A. Tarver B.S.,B.A. May, 1991 Tarver, John A. Chemical Ionization (CI) GC/MS Analysis of Underivatized Amphetamines Followed by Chiral Derivatiza- tion to Identify d and 1-Isomers with Ion Trap Mass Spectro- metry. Master of Science (Biomedical Sciences), May, 1991, 26 pp., 9 figures, bibliography, 20 titles. An efficient two step procedure has been developed using CI GC/MS for analyzing amphetamines and related compounds. The first step allows the analysis of underiv- atized amphetamines with the necessary sensitivity and specificity to give spectral identification, including differentiation between methamphetamine and phentermine. The second step involves preparing a chiral derivative of the extract to identify d and 1-isomeric composition. TABLE OF CONTENTS Page LIST OF ILLUSTRATIONS.......... ... .. .. .......... iv INTRODUCTION .1........................... EXPERIMENTAL MATERIALS ...--- - - - - ----... -....-..... 15 METHODS --------------------.---...... 15 RESULTS AND DISCUSSION ...-..-..................... 17 CONCLUSION - - - - - -- - - - - --- - --- . - . 23 APPENDIX......... ---. -----....-.-. ----.. -........ 24 REFERENCES ----------------------------.. --. ...---.. 28 iii LIST OF ILLUSTRATIONS
    [Show full text]
  • New Drugs in Europe, 2012 Europe, in Drugs New
    ISSN 1977-7841 New drugs in Europe, 2012 EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA 2012 New drugs in Europe, 2012 EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, the EU Member States or any institution or agency of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu). Europe Direct is a service to help you find answersto your questions about the European Union. Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed. Cataloguing data can be found at the end of this publication. Luxembourg: Publications Office of the European Union, 2013 ISBN 978-92-9168-650-6 doi:10.2810/99367 © European Monitoring Centre for Drugs and Drug Addiction, 2013 Cais do Sodré, 1249-289 Lisbon, Portugal Tel. +351 211210200 • [email protected] • www.emcdda.europa.eu © Europol, 2013 Eisenhowerlaan 73, 2517 KK, The Hague, the Netherlands Tel.
    [Show full text]
  • TURKEY MINISTRY of INTERIOR TURKISH NATIONAL POLICE Anti-Smuggling and Organized Crime Department
    REPUBLIC OF TURKEY MINISTRY OF INTERIOR TURKISH NATIONAL POLICE Anti-Smuggling and Organized Crime Department 2014 NATIONAL REPORT (2013 data) TO THE EMCDDA by the Reitox National Focal Point TURKEY New Development, Trends and in-depth information on selected issues TURKISH MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION (TUBİM) REITOX 1 TABLE OF CONTENTS TABLE OF CONTENTS ........................................................................................................... 2 TURKISH NATIONAL FOCAL POINT STAFF PREPARING THE REPORT ........................... 7 DATA PROVIDING AGENCIES AND AGENCY REPRESENTATIVES ................................... 8 PREFACE .............................................................................................................................. 11 ABBREVIATIONS .................................................................................................................. 13 SUMMARY ............................................................................................................................. 15 NEW DEVELOPMENTS AND TRENDS ................................................................................ 29 SECTION 1 ............................................................................................................................ 29 DRUG POLICY: LAWS, STRATEGIES, AND ECONOMIC ANALYSES ............................... 29 1.1. Introduction ................................................................................................................ 29 1.2. Legal Framework
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • JPET #185728 1 Title Page the Effects of Repeated MDMA (3,4
    JPET Fast Forward. Published on October 7, 2011 as DOI: 10.1124/jpet.111.185728 JPET FastThis article Forward. has not beenPublished copyedited on and October formatted. The7, 2011final version as DOI:10.1124/jpet.111.185728 may differ from this version. JPET #185728 Title Page The effects of repeated MDMA (3,4-methylenedioxymethamphetamine) administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus1 Downloaded from . jpet.aspetjournals.org Starr M.A, Page M.E., Waterhouse B.D Drexel University College of Medicine Laboratory of Barry D. Waterhouse, Ph.D (B.D.W., M.E.P., M.A.S.) at ASPET Journals on September 27, 2021 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on October 7, 2011 as DOI: 10.1124/jpet.111.185728 This article has not been copyedited and formatted. The final version may differ from this version. JPET #185728 Running Title Page Effects of MDMA on sensory processing in VPM thalamus Barry D. Waterhouse Drexel University College of Medicine 2900 Queen Lane; Department of Neurobiology and Anatomy Philadelphia, PA 19129 1(215)991-8411 (work) 1(215)843-9082(fax) Downloaded from [email protected] 7 Figures 39 pages jpet.aspetjournals.org Abstract: 250 words Introduction: 496 words Discussion: 1460 words References: 30 at ASPET Journals on September 27, 2021 Recommended section assignment: Neuropharmacology List of Abbreviations List of Chemical Compounds aCSF: artificial cerebrospinal fluid Butyric
    [Show full text]
  • Simultaneous Analysis of Seven Amphetamine Class Drugs in Urine for Forensic Toxicology Jeremy Netto, Waters Corporation
    Simultaneous Analysis of Seven Amphetamine Class Drugs in Urine for Forensic Toxicology Jeremy Netto, Waters Corporation GOAL Increased Analytical Sensitivity for Analysis of To demonstrate that the use of an online SPE Amphetamines Enabled with Sample Preparation system (ACQUITY® Online SPE Manager) efficiently removes sample matrix effects and improves the LC/MS analysis of amphetamines in urine BACKGROUND H Amphetamines increase activity related to the NH2 O N neurotransmitters dopamine and norepinephrine O in the brain. Well known in popular culture (as Speed) and often abused in the 1960’s and Amphetamine MDMA 70’s, current usage of amphetamines is strictly regulated and monitored. However, in the past few years, amphetamine NH2 and its many derivatives (metamphetamine, Phentermine MDMA, MDA, etc.) have become extraordinarily popular as recreational and illicit drugs around Figure 1: Structure of Some Amphetamine Class Drugs. the world. Unfortunately, these psychoactive drugs are commonly manufactured by illegal drug manufacturing operations and often find their way onto the market in very potent form. Higher doses dangerous both to manufacturers and users. A number of deaths, or cases of of amphetamine class drugs used recreationally serious overdose, related to these drugs has led to a greater need for detection in to achieve a sense of euphoria or highly energetic some populations. In many parts of the world, use of these types of drugs at state are potentially very toxic, habit forming, parties and in nightclubs has reached epidemic proportions and the need for and even fatal. Some compounds in this class, effective testing to identify these compounds in criminal or forensics cases has such as methamphetamine, are particularly become crucial.
    [Show full text]
  • Stimulant Analytical Standards
    Stimulant Analytical Standards Stimulants belong to a diverse group of psychoactive drugs whose function exerts a constant contribution to hyperactivity and impulse control. Illegal stimulant derivatives including amphetamines, arylcyclohexylamines, cathinones, cocaine/tropanes, phenethylamines, and piperazines are among the most widely abused across the US and Europe. However, the popularity of each substance, particularly in party culture settings, is frequently changing. Cayman offers more than 700 analytical standards for the identification of stimulants and is dedicated to working with the forensic community to quickly make reference standards available for new psychoactive substances (NPS). A library of mass spectral data containing many of Cayman’s emerging stimulant standards is freely available for download at www.caymanchem.com/CSL. More than 700 Stimulant Standards Available for · Amphetamines · Indanes · Arylcyclohexylamines · Phenethylamines · Cathinones · Piperazines · Cocaine & Tropanes · And More Tools to Rapidly Screen for Major Controlled Stimulants Cocaine/Heroin/Methamphetamine Mixture (CRM) Item No. 9002662 A CRM mixture of cocaine, heroin, and methamphetamine (1 mg/ml of each) GC-MS Drug Standard Mixture 4 Item No. 24632 A mixture of common stimulants, opioids, and Representative chromatogram of the compounds steroids as well as a synthetic cannabinoid and a included in the GC-MS Drug Standard Mixture 4 benzodiazepine (250 μg/ml of each) Peak order from left to right: α-Pyrrolidinobutiophenone, α-Pyrrolidinopentiophenone,
    [Show full text]
  • New Psychoactive Substances (NPS)
    New Psychoactive Substances (NPS) LGC Quality Reference ISO 9001 ISO/IEC 17025 ISO Guide 34 materials GMP/GLP ISO 13485 2019 ISO/IEC 17043 Science for a safer world LGC offers the most extensive and up-to-date range of New LGC is a global leader in Psychoactive Substances (NPS) measurement standards, reference materials. reference materials, laboratory services and proficiency testing. With 2,600 professionals working When you make a decision using The challenge The LGC response We are the UK’s in 21 countries, our analytical our resources, you can be sure it’s designated National measurement and quality control based on precise, robust data. And New Psychoactive Substances In response to the ever-expanding LGC Standards provides the widest Measurement services are second-to-none. together, we’re creating fairer, safer, (NPS) continue to be identified, range of NPS being developed, LGC range of reference materials Institute for chemical more confident societies worldwide. and it appears that moves by the has produced a comprehensive available from any single supplier. and bioanalytical As a global leader, we provide the United Nations and by individual range of reference materials that We work closely with leading widest range of reference materials lgcstandards.com countries to control lists of meet the rapidly changing demands manufacturers to provide improved measurement. available from any single supplier. named NPS may be encouraging of the NPS landscape. Many of access to reference materials, the development of yet further these products are produced under with an increasingly large range variants to avoid these controls. the rigorous quality assurance of parameters, for laboratories standards set out in ISO Guide 34.
    [Show full text]
  • NMAM 9106: METHAMPHETAMINE and Illicit Drugs, Precursors
    METHAMPHETAMINE and Illicit Drugs, Precursors 9106 and Adulterants on Wipes by Liquid-Liquid Extraction FORMULA: Table 1 MW: Table 1 CAS: Table 1 RTECS: Table 1 METHOD: 9106, Issue 1 EVALUATION: Partial Issue 1: 17 October 2011 OSHA: none for surfaces PROPERTIES: Table 2 NIOSH: none for surfaces Other OELs and guidelines: [1, 2, 3] SYNONYMS: Table 3 SAMPLING MEASUREMENT SAMPLER: Wipe TECHNIQUE: GAS CHROMATOGRAPHY/MASS SPECTROMETRY SAMPLE AREA: 100 cm² or 1000 cm² ANALYTES: Table 1 SHIPMENT: Preferably ship refrigerated, <6 °C DESORPTION: 0.1 M sulfuric acid SAMPLE CLEANUP/ STABILITY: 30 days at <6 °C (See Table 4) EXTRACTION: Hexane cleanup followed by methylene chloride extraction FIELD BLANKS: 2 to 10 blanks per sample set DERIVATIZATION: Chlorodifluoroacetic anhydride MEASUREMENT ACCURACY INJECTION: 2 µL, splitless LEVEL STUDIED: 3 μg/sample on smooth surfaces TEMPERATURE - Injection: 265 °C BIAS: Table 10a and 10b - Detector: 285 °C - Column: 90 °C (2 min), 310 °C (10 °C/min), OVERALL hold for 11 min PRECISION ( ): Table 7a and 7b [4] MASS ACCURACY: Table 7a and 7b [4] SPECTROMETER: Scan mode (29 – 470 AMU), 2 scan per sec, Selected ion monitoring (SIM) mode Table 5 CARRIER GAS: Helium, 1.5 mL/min COLUMN: Capillary, fused silica, 30 m × 0.32 mm ID; 0.5 μm film phenyl arylene polymer CALIBRATION: Standards from spiked wipes with internal standard, See Table 6 RANGE: Table 7a and 7b [4] ESTIMATED LOD: Table 4 PRECISION ( ): Table 7a and 7b [4] APPLICABILITY: For methamphetamine, the range is 0.05 to 60 μg/sample (sample = 100 cm2 or 1000 cm2).
    [Show full text]